Table 3.

Differentially expressed genes in CAL-51 cells treated with everolimus and gefitinib alone and in combination.

Genea	Everob	Gefb	E + Gb	p /Everoc	p /Gefc
EGFR	1,0	0,5	2,0	0,178	0,113
MYC	1,2	0,5	1,7	0,361	0,121
CDKN1C	0,9	0,0	1,2	0,474	0,048
CASP9	0,7	0,4	1,1	0,445	0,117
KRAS	0,4	0,5	1,0	0,503	0,556
IGFR	0,5	0,3	1,0	0,080	0,060
VEGFA	0,1	0,2	1,0	0,056	0,219
CDH1	0,4	−0,3	1,0	0,390	0,245
TP53	0,2	0,5	0,9	0,003	0,164
BRAF	0,4	0,6	0,9	0,493	0,435
CCNE1	−0,3	−0,1	−1,0	0,247	0,050
CHEK1	−0,6	−0,3	−1,0	0,357	0,086
CHEK2	−0,6	−0,3	−1,0	0,268	0,358
CCNA1	−1,1	0,2	−1,2	0,713	0,024
FOS	0,8	−1,4	−1,4	0,081	0,826
CCNB1	−1,1	−0,4	−1,7	0,148	0,015

^aList of genes that were 2-fold up- or downregulated after combination treatments.

^bData are presented as log2 of the average relative quantification after everolimus (100 nM) and gefitinib (5 µM) treatments as single agents (Evero; Gef) and in combination (E + G). A value of 1 corresponds to a two-fold upregulation and a value of −1 corresponds to a two-fold downregulation.

^cStatistical differences between combination and everolimus (p/Evero) or gefitinib (p/Gef) treatments were assessed using Student’s t-test.